The HinduHealth
India rejects patent for shorter TB treatment
India’s rejection of a patent application for a shorter drug-resistant tuberculosis treatment may allow more generic versions to enter the market. But lower treatment costs are not guaranteed; they will depend on medicine supplies, prices, and patients’ access to care.
This card is an AI-assisted summary of reporting published by The Hindu. Read the original report before relying on it for medical, legal, financial, safety, or emergency decisions.